Evaluating microvascular function in heart transplant patients
Official title: Physiologic Assessment of Microvascular Function and Its Impact on Cardiac Allograft Vasculopathy in Heart Transplant Patients: Prospective Registry and Pilot Study
Run by Samsung Medical Center · NCT02798731 · Data updated 2026-11-12
This study is testing new ways to check blood flow in heart transplant patients to see if it can help spot early signs of heart problems that could lead to serious health issues.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Samsung Medical Center Academic / other |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | May 2016 |
| Main results expected | June 2030 |
| Study ends | December 2030 |
| Registry record updated | March 14, 2025 |
| Trial ID | NCT02798731 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over the age of 18 who have received a heart transplant.
✕Probably not a fit
Patients experiencing cardiogenic shock, unstable vital signs, or those with severe valvular heart disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess early microvascular disease in heart transplant recipients by measuring coronary physiologic indices such as fractional flow reserve (FFR), coronary flow reserve (CFR), and index of microvascular resistance (IMR). The focus is on understanding how these indices relate to the future occurrence of cardiac allograft vasculopathy (CAV), a significant cause of morbidity and mortality in this population. By utilizing these advanced diagnostic techniques, the study seeks to improve early detection and management of CAV, which often presents without typical ischemic symptoms. The findings could lead to better screening protocols and interventions for heart transplant patients.
Why it matters
Potential benefit: If successful, this study could enhance early detection and management of cardiac allograft vasculopathy, potentially improving outcomes for heart transplant patients.
How similar studies have gone: Other studies have explored microvascular function in heart transplant patients, but this specific approach using FFR, CFR, and IMR is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject over age of 18 * Patients received heart transplant Exclusion Criteria: * Patients with cardiogenic shock * Patients with unstable vital sign that precludes coronary angiography * Patients with major bleeding in last 3 months * Patients with active bleeding * Patients with coagulopathy * Patients with severe valvular heart disease * Patients who refused to provide informed consent
Where it's running
-
Samsung Medical Center
Seoul, South Korea Recruiting
Study contacts
- Principal investigator: Joo Myung Lee, MD, MPH — Samsung Medical Center
- Study coordinator: Joo Myung Lee, MD, MPH
- Email: drone80@hanmail.net
- Phone: 82-2-3410-1246
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using PET scans to monitor heart transplant patients for complications
This study is testing if regular PET scans can safely monitor heart transplant patients for complications instead of the usual invasive procedures.
-
Investigating antiplatelet therapy to prevent complications in heart transplant patients
This study tests if giving heart transplant patients early treatment with aspirin or clopidogrel can help prevent a common problem where their heart arteries narrow.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer
This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.
-
Wearable eye tracking during bimanual tasks in children with cerebral palsy
This study tests whether wearable eye-tracking glasses can reliably record eye movements while children with CP and typically developing peers perform two-handed tasks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.